| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Fibrinogen is converted to fibrin by thrombin during blood clotting. Thrombin activation assembles fibrinogen into a fibrin clot. The conversion of soluble fibrinogen to the insoluble clot-forming fibrin is the terminal stage of blood clotting. Fibrinogen consists of three peptide chains, a (A), b (B), and g (C), crosslinked by several disulfide bonds.
|
|---|---|
| ln Vitro |
In vitro, Fibrinogen is a selective proteolytic molecule whose thrombin activation assembles into a fibrin clot. Fibrinogen from any mammalian source is cleaved by thrombin from any mammalian source. The amount of fibrinogen in plasma can serve as a nonspecific indicator of an inflammatory process.
|
| ln Vivo |
In vivo, Fibrinogen is essential for blood clotting. It is an acute phase protein whose synthesis is greatly increased during acute inflammatory challenge. Fibrinogen concentrate (human) is a hematological agent that works by replacing a certain protein in the blood that helps with blood clotting.
|
| Enzyme Assay |
Fibrinogen's conversion to fibrin by thrombin can be characterized in vitro. Thrombin activation involves the proteolytic release of two negatively charged fibrinopeptides, fibrinopeptide A from the α-chain and fibrinopeptide B from the β-chain. The removal of fibrinopeptide A is necessary for fibrin polymerization.
|
| Cell Assay |
In vitro cell experiments with Fibrinogen are limited as it is a plasma protein. Cell-based assays may involve studying platelet aggregation or clot formation in the presence of fibrinogen and thrombin.
|
| Animal Protocol |
In vivo animal studies with Fibrinogen have been conducted in the context of hemostasis and thrombosis research. Fibrinogen levels are measured as an indicator of inflammation and clotting disorders.
|
| ADME/Pharmacokinetics |
Fibrinogen has a plasma half-life of approximately 3-5 days. It is synthesized in the liver and cleared from the circulation. The amount of fibrinogen in plasma can serve as a nonspecific indicator of inflammation.
|
| Toxicity/Toxicokinetics |
Fibrinogen is considered safe for research use at typical concentrations. As a plasma protein, it is naturally present in the body. Fibrinogen concentrate is used clinically as a hematological agent.
|
| References | |
| Additional Infomation |
D-Idoutitol is the D-enantiomer of idoutitol, a fungal metabolite, and also the enantiomer of L-idoutitol. It has been reported in Stypopodium flabelliforme and Stypopodium schimperi, with relevant data available. Thrombin-coagulated plasma glycoproteins consist of dimers formed by three pairs of different polypeptide chains (α, β, γ) linked by disulfide bonds. Fibrinogen coagulation is a sol-gel transition process involving complex molecular arrangements: fibrinogen is cleaved by thrombin to form polypeptides A and B, while proteolytic action by other enzymes produces various fibrinogen degradation products. See also: sorbitol (note moved to); fibrinogen (note moved to).
Fibrinogen (Factor I) is a soluble plasma glycoprotein synthesized in the liver. It is an acute phase protein and part of the coagulation cascade. It is converted to fibrin by thrombin during blood clotting. It has an approximate molecular mass of 340 kDa and consists of three peptide chains. |
| Molecular Formula |
C6H14O6
|
|---|---|
| Molecular Weight |
182.1718
|
| Exact Mass |
233.813
|
| CAS # |
9001-32-5
|
| PubChem CID |
90540
|
| Appearance |
White to off-white solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
186.8±0.0 °C at 760 mmHg
|
| Flash Point |
61.3±15.8 °C
|
| Vapour Pressure |
0.9±0.3 mmHg at 25°C
|
| Index of Refraction |
1.533
|
| LogP |
4.47
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
12
|
| Complexity |
105
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C([C@H]([C@@H]([C@H]([C@@H](CO)O)O)O)O)O
|
| InChi Key |
FBPFZTCFMRRESA-ZXXMMSQZSA-N
|
| InChi Code |
InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4-,5+,6+/m1/s1
|
| Chemical Name |
(2R,3S,4S,5R)-hexane-1,2,3,4,5,6-hexol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : < 0.1 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.4894 mL | 27.4469 mL | 54.8938 mL | |
| 5 mM | 1.0979 mL | 5.4894 mL | 10.9788 mL | |
| 10 mM | 0.5489 mL | 2.7447 mL | 5.4894 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
